Supporting cost-effectiveness evaluations of human papillomavirus in low and middle income countries

PI: Mark Jit
Funding: WHO

WHO recommends that cost-effectiveness is considered before human papillomavirus (HPV) vaccination is introduced into national schedules. However, resources for cost-effectiveness evaluations are often limited in many low and middle income countries. This project aims to understand current cost-effectiveness evidence behind HPV vaccination options in such countries, to compare existing economic models of HPV vaccination as well as to develop guidelines for conducting and interpreting the results of these studies. As part of this project, LSHTM together with WHO, Université Laval and John Hopkins University have developed PRIME (Papillomavirus Rapid Interface for Modelling and Economics), a user-friendly tool to evaluate the cost-effectiveness of HPV vaccine introduction for young adolescent girls. Future plans include refining PRIME following piloting the tool in countries that are interested in using it.